医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Meitheal Pharmaceuticals Announces Completion of Majority Stake Investment from Nanjing King-Friend Biochemical Pharmaceutical Company

2019年10月31日 PM10:54
このエントリーをはてなブックマークに追加


 

CHICAGO

Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, Illinois today announced the completion of a previously announced majority stake investment from Hong Kong King-Friend Industrial Company (HKF), a wholly-owned subsidiary of China-based manufacturer Nanjing King-Friend Biochemical Pharmaceutical Company (NKF). Following the completion of the $95 million transaction, Meitheal is now majority-owned by NKF and will serve as its exclusive commercialization arm in the US.

ABOUT MEITHEAL PHARMACEUTICALS

Since 2017, Meitheal Pharmaceuticals has bridged critical gaps in the US healthcare market by supplying high quality, affordable generic injectables. Our diversified product range — from antibiotics, anticoagulants, and muscle relaxants to drugs used in chemotherapy — represents practical solutions for countless patients around the country, as well as Meitheal’s commitment to their care. Based in Chicago, Illinois, our aim each day is producing quality and ensuring affordability, using the traditional Irish guiding principle we are named for — Meitheal (Mee·hall): working together toward a common goal, for the greater good.

Learn more about who we are and what we do at www.meithealpharma.com.

ABOUT NANJING KING-FRIEND BIOPHARMACEUTICAL COMPANY (NKF)

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (NKF) is a China-based company principally engaged in the research and development, production and sales of Active Pharmaceutical Ingredients (API) and Finished Dosage Form (FDF). Established in 1986 as one of world leading manufacturers of heparin related APIs, NKF has grown into a fully integrated API and FDF manufacturer in multiple therapeutic areas including critical care and oncology. With three US FDA approved manufacturing sites in China and more than 500 employees, including more than 100 dedicated research and development experts, NKF strives to meet patient needs globally with market presence at US, China, EU and South America. The Company is publicly listed on Shanghai Stock Exchange with a market capitalization over $3B.

ABOUT HONG KONG KING-FRIEND INDUSTRIAL COMPANY

Hong Kong King-Friend Industrial Company is a wholly-owned subsidiary of NKF, founded in 2010.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005608/en/

CONTACT

MEDIA

Camilla White

FTI Consulting

646 250 0050

camilla.white@fticonsulting.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
  • Personalis, Inc.新发表的数据显示,新型复合生物标志物NEOPS™可用于预测晚期黑色素瘤患者对癌症免疫治疗药物的应答
  • Society5.0 Acquires a Business Model Patent to Build an AR System That Uses Voice Recognition Technology to Provide Medical Safety, Contributing to the Realization of DX
  • 武田交出稳健的2021财年第一季度业绩,促使公司加速营收增长并延续其在研产品线发展态势
  • Oscar Wylee Announces 100th Store; Further Expansion Planned